Author | Michio Mito, MD, PhD

Articles

UFT and Mitomycin Plus Tamoxifen for Stage II, ER-Positive Breast Cancer

July 01, 1999

ByYoshinobu Hata, MD, PhD

Junichi Uchino, MD, PhD

Kazuaki Asaishi, MD, PhD

Yoshihiko Kubo, MD, PhD

Michio Mito, MD, PhD

Tatsuzo Tanabe, MD, PhD

Masami Ogita, MD, PhD

Koichi Hirata, MD

A trial was designed to examine the combination of UFT and mitomycin (Mutamycin) plus tamoxifen (Nolvadex) as postoperative adjuvant therapy in the treatment of patients with stage II, estrogen receptor (ER)-positive